Quantcast
Last updated on April 17, 2014 at 11:32 EDT

Latest Bevacizumab Stories

2012-11-16 08:23:38

PARIS and TARRYTOWN, N.Y., Nov. 16, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended the granting of marketing authorization for ZALTRAP(®) (ziv-aflibercept) Injection for Intravenous Infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI)...

2012-11-15 12:27:35

VANCOUVER, British Columbia, Nov. 15, 2012 /PRNewswire/ -- Del Mar Pharmaceuticals (BC) Ltd. ("DelMar Pharma") today announced that the Company will present two scientific posters at the Society for Neuro-Oncology (SNO) 17(th) Annual Scientific Meeting, which is being held in Washington, DC November 15-18, 2012. On Friday November 16(th), DelMar will present a poster entitled, "VAL-083, Novel N7 Alkylating Agent, Surpasses Temozolomide Activity and Inhibits Cancer Stem Cells Providing a...

2012-11-15 12:27:22

TORONTO, Nov. 15, 2012 /PRNewswire/ -- In response to the November 11, 2012 press release issued by the American Academy of Ophthalmology (AAO) Task Force on Genetic Testing, ArcticDx Inc. (Arctic) maintains that Macula Risk®, its laboratory developed test (LDT) for AMD, is of the highest standard and proven to add to the accuracy of clinical assessment alone in its intended use of risk stratification for AMD patients. While in general agreement with the Task Force's Recommendations for...

2012-11-09 20:22:08

MANHATTAN BEACH, Calif., Nov. 9, 2012 /PRNewswire/ -- The Pancreatic Cancer Action Network is pleased to announce Abraxane® extends survival for patients with advanced pancreatic cancer. According to Celgene Corporation, Abraxane in combination with gemcitabine when given to advanced pancreatic cancer patients who had not received previous treatment demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone. (Logo:...

2012-11-08 08:35:29

VANCOUVER, British Columbia, Nov. 8, 2012 /PRNewswire/ -- Del Mar Pharmaceuticals (BC) Ltd. (DelMar) today announced that Mr. Jeffrey Bacha, the Company's President & CEO, delivered the keynote address entitled VAL-083 a Novel Chemotherapeutic Agent Developed in China for CML and Lung Cancer Shows Potential to Surpass Standard of Care in Glioblastoma Multiforme at the 2012 International Drug Discovery Science and Technology Conference in Nanjing, China. In his address, Mr. Bacha...

2012-10-26 00:40:03

Findings from a nationwide study led by researchers at Dana-Farber Cancer Institute suggest that patients with advanced lung or colorectal cancer are frequently mistaken in their beliefs that chemotherapy can cure their disease. The study, published in the Oct. 25 issue of the New England Journal of Medicine, found that 69 percent of patients with advanced lung cancer and 81 percent of patients with advanced colorectal cancer did not understand that the chemotherapy they were receiving was...

2012-10-15 07:28:52

INDIANAPOLIS, Oct. 15, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with metastatic gastric cancer, met its primary endpoint of improved overall survival and also showed prolonged progression-free survival. This trial is the first Phase III data read-out for ramucirumab. The REGARD trial compared ramucirumab and best supportive care to placebo and best supportive care as a second-line...

2012-10-09 15:25:17

SAN DIEGO, Oct. 9, 2012 /PRNewswire/ -- Consumers are turning to alternative sources to buy their medications. These sources include the internet and/or pharmacies that are compounding medicines. Unfortunately, the consumer has little knowledge about all the hazards to one's health with these alternatives. "It is critical that your doctor is aware of all the medications you are taking and confirms their origins," said Dr. Sandy T. Feldman of ClearView Eye & Laser Medical...

2012-09-27 06:28:54

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., Sept. 27, 2012 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the U.S. Food and Drug Administration (FDA) approved Bayer's Stivarga(®) (regorafenib) tablets for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with currently available therapies (including fluoropyrimidine-, oxaliplatin- and irinotecan-based...

2012-09-24 02:26:40

NEW YORK, Sept. 24, 2012 /PRNewswire/ -- Ohr Pharmaceutical (OTCBB: OHRP-News) today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration ("wet-AMD"). The randomized, double blind, placebo controlled study will enroll patients at twenty one ophthalmology treatment centers across the United States. Interim results are expected in the fourth quarter of 2013. "An...